Prognostic significance of pretreatment lymphocyte percentage and age at diagnosis in patients with locally advanced cervical cancer treated with definite radiotherapy.
- Author:
Myung Hwa JEONG
1
;
Hyungjoo KIM
;
Tae Hun KIM
;
Moon Hong KIM
;
Beob Jong KIM
;
Sang Young RYU
Author Information
- Publication Type:Original Article
- Keywords: Hematologic test; Lymphocytes; Cervical cancer; Radiotherapy; Aging; Prognosis
- MeSH: Aging; Blood Cell Count; Chemoradiotherapy; Diagnosis*; Disease-Free Survival; Electronic Health Records; Hematologic Tests; Humans; Lymph Nodes; Lymphocytes*; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Radiotherapy*; Retrospective Studies; ROC Curve; Treatment Failure; Uterine Cervical Neoplasms*
- From:Obstetrics & Gynecology Science 2019;62(1):35-45
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: This study aimed to evaluate the prognostic impact of age at diagnosis, and pretreatment hematologic markers, including lymphocyte percentage and the neutrophil-to-lymphocyte ratio (NLR), in patients with locally advanced cervical cancer (LACC) treated with definitive radiotherapy (RT). METHODS: A total of 392 patients with LACC (stage IIb to IVa) treated with cisplatin-based concurrent chemoradiotherapy or RT alone between 2001 and 2012 were retrospectively enrolled. Clinical data and pretreatment complete blood counts were extracted from electronic medical records of the patients, and analyzed. Treatment outcomes, progression-free survival (PFS), and overall survival (OS) were evaluated. RESULTS: Low lymphocyte percentage and a high NLR were associated with younger age, advanced stage, larger tumor size, lymph nodes metastasis, and treatment failure. The cut-off value for lymphocyte percentage and NLR was determined using a receiver operating characteristic curve. In univariate analysis, low lymphocyte percentage (≤24%) was associated with poor PFS and OS, while high NLR ( > 2.8) was significantly associated only with PFS. In multivariate analysis, both lymphocyte percentage (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.40–0.85; P=0.005) and NLR (HR, 1.55; 95% CI, 1.07–2.25; P=0.022) had independent prognostic value for PFS. Compared to younger patients (age ≤50 years), older patients (age > 60 years) had a lower risk of death. CONCLUSION: Although the lymphocyte percentage did not remain significant in multivariate analysis for OS, it was predictive of PFS and OS. Thus, lymphocyte percentage is a simple hematologic parameter with a significant prognostic value in patients with LACC treated with definitive RT.
